This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.
This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.
Produktdetails
Produktdetails
Resistance to Targeted Anti-Cancer Therapeutics 13
Augusto Villanueva, MD, PhD, is Assistant Professor, Division of Liver Diseases, Liver Cancer Program, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine, NYC.
Inhaltsangabe
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma.- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma.- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance.- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance.- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma.- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma.- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma.- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma.- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma.- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance.- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance.- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma.- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma.- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma.- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma.- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma.- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance.- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance.- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma.- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma.- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma.- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma.- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma.- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance.- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance.- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma.- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma.- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma.- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
